{"id":"NCT03657160","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-06","primaryCompletion":"2022-02-07","completion":"2022-05-09","firstPosted":"2018-09-04","resultsPosted":"2023-04-14","lastUpdate":"2023-06-06"},"enrollment":343,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Hematopoietic Stem Cells"],"interventions":[{"type":"DRUG","name":"Vedolizumab Placebo","otherNames":[]},{"type":"DRUG","name":"Vedolizumab","otherNames":["MLN0002"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vedolizumab 300 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.","primaryOutcome":{"measure":"Intestinal aGvHD-Free Survival After Allo-HSCT by +180 Days","timeFrame":"From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to +180 days","effectByArm":[{"arm":"Placebo","deltaMin":null,"sd":null},{"arm":"Vedolizumab 300 mg","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":139,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Norway","Poland","Portugal","Romania","Russia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["38844797"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":114,"n":165},"commonTop":["Diarrhoea","Stomatitis","Nausea","Pyrexia","Anaemia"]}}